Nuwellis price target lowered to $11 from $13 at Roth Capital

Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on Nuwellis (NUWE) to $11 from $13 and keeps a Buy rating on the shares. While the company’s Q1 revenue was down 18% quarter over quarter, pediatric utilization grew 38% year over year, the analyst tells investors in a research note. The firm believes that the four-fold increase in Aquadex Centers for Medicare & Medicaid Services reimbursement should support future revenue growth.